Heidler, C. L., Roth, E. K., Thiemann, M., Blattmann, C., Lopez Perez, R., Huber, P. E., . . . Kulozik, A. (2019). Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. International journal of cancer, 147(4), . https://doi.org/10.1002/ijc.32814
Chicago-Zitierstil (17. Ausg.)Heidler, Christopher L., et al. "Prexasertib (LY2606368) Reduces Clonogenic Survival by Inducing Apoptosis in Primary Patient-derived Osteosarcoma Cells and Synergizes with Cisplatin and Talazoparib." International Journal of Cancer 147, no. 4 (2019). https://doi.org/10.1002/ijc.32814.
MLA-Zitierstil (9. Ausg.)Heidler, Christopher L., et al. "Prexasertib (LY2606368) Reduces Clonogenic Survival by Inducing Apoptosis in Primary Patient-derived Osteosarcoma Cells and Synergizes with Cisplatin and Talazoparib." International Journal of Cancer, vol. 147, no. 4, 2019, https://doi.org/10.1002/ijc.32814.